Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study
BackgroundSarcoma is a highly heterogeneous malignancy with a poor prognosis. Although chemotherapy and targeted therapy have improved the prognosis to some extent, the efficacy remains unsatisfactory in some patients. The efficacy and safety of immunotherapy in sarcoma need further evaluation.Metho...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1292325/full |
| _version_ | 1797249292512002048 |
|---|---|
| author | Zhichao Liao Zhichao Liao Jianjin Teng Tao Li Haotian Liu Haotian Liu Ting Li Ting Li Chao Zhang Chao Zhang Ruwei Xing Ruwei Xing Sheng Teng Sheng Teng Yun Yang Yun Yang Jun Zhao Jun Zhao Wanyi Xiao Wanyi Xiao Gengpu Zhang Gengpu Zhang Mulin Jun Li Weitao Yao Jilong Yang Jilong Yang |
| author_facet | Zhichao Liao Zhichao Liao Jianjin Teng Tao Li Haotian Liu Haotian Liu Ting Li Ting Li Chao Zhang Chao Zhang Ruwei Xing Ruwei Xing Sheng Teng Sheng Teng Yun Yang Yun Yang Jun Zhao Jun Zhao Wanyi Xiao Wanyi Xiao Gengpu Zhang Gengpu Zhang Mulin Jun Li Weitao Yao Jilong Yang Jilong Yang |
| author_sort | Zhichao Liao |
| collection | DOAJ |
| description | BackgroundSarcoma is a highly heterogeneous malignancy with a poor prognosis. Although chemotherapy and targeted therapy have improved the prognosis to some extent, the efficacy remains unsatisfactory in some patients. The efficacy and safety of immunotherapy in sarcoma need further evaluation.MethodsWe conducted a two-center study of sarcoma patients receiving PD-1 immunotherapy at Tianjin Medical University Cancer Institute and Hospital and Henan Provincial Cancer Hospital. The treatment regimens included PD-1 inhibitor monotherapy and combination therapy based on PD-1 inhibitors. The observed primary endpoints were median progression-free survival (mPFS) and median overall survival (mOS). Survival curves were compared using the Kaplan−Meier method.ResultsA total of 43 patients were included from the two centers. The median follow-up time for all patients was 13 months (range, 1-48 months). In the group of 37 patients with advanced or unresectable sarcoma, the mPFS was 6 months (95%CI: 5-12 months), and the mOS was 16 months (95%CI: 10-28 months). The ORR was 10.8% (4/37), and the DCR was 18.9% (7/37). Subgroup analysis showed no significant differences in mPFS (p=0.11) and mOS (p=0.88) between patients with PD-L1 negative/positive expression. There were also no significant differences in mPFS (p=0.13) or mOS (p=0.72) between PD-1 inhibitor monotherapy and combination therapy. Additionally, there were no significant differences in mPFS (p=0.52) or mOS (p=0.49) between osteogenic sarcoma and soft tissue sarcoma. Furthermore, the results showed no significant differences in mPFS (p=0.66) or mOS (p=0.96) between PD-1 inhibitors combined with targeted therapy and PD-1 inhibitors combined with AI chemotherapy. Among the 6 patients receiving adjuvant therapy after surgery, the mPFS was 15 months (95%CI: 6-NA months), and the mOS was not reached. In terms of safety, most adverse events were mild (grade 1-2) and manageable. The most severe grade 4 adverse events were bone marrow suppression, which occurred in 4 patients but resolved after treatment. There was also one case of a grade 4 adverse event related to hypertension.ConclusionImmunotherapy is an effective treatment modality for sarcoma with manageable safety. Further inclusion of more patients or prospective clinical trials is needed to validate these findings. |
| first_indexed | 2024-04-24T20:28:10Z |
| format | Article |
| id | doaj.art-9a44e26d31ed4aea83d878e10b23e41a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T20:28:10Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-9a44e26d31ed4aea83d878e10b23e41a2024-03-22T04:31:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-03-011510.3389/fimmu.2024.12923251292325Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center studyZhichao Liao0Zhichao Liao1Jianjin Teng2Tao Li3Haotian Liu4Haotian Liu5Ting Li6Ting Li7Chao Zhang8Chao Zhang9Ruwei Xing10Ruwei Xing11Sheng Teng12Sheng Teng13Yun Yang14Yun Yang15Jun Zhao16Jun Zhao17Wanyi Xiao18Wanyi Xiao19Gengpu Zhang20Gengpu Zhang21Mulin Jun Li22Weitao Yao23Jilong Yang24Jilong Yang25Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, ChinaDepartment of Bone and Soft-Tissue Tumor, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, ChinaDepartment of Bone and Soft Tissue Cancer, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaNational Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaBackgroundSarcoma is a highly heterogeneous malignancy with a poor prognosis. Although chemotherapy and targeted therapy have improved the prognosis to some extent, the efficacy remains unsatisfactory in some patients. The efficacy and safety of immunotherapy in sarcoma need further evaluation.MethodsWe conducted a two-center study of sarcoma patients receiving PD-1 immunotherapy at Tianjin Medical University Cancer Institute and Hospital and Henan Provincial Cancer Hospital. The treatment regimens included PD-1 inhibitor monotherapy and combination therapy based on PD-1 inhibitors. The observed primary endpoints were median progression-free survival (mPFS) and median overall survival (mOS). Survival curves were compared using the Kaplan−Meier method.ResultsA total of 43 patients were included from the two centers. The median follow-up time for all patients was 13 months (range, 1-48 months). In the group of 37 patients with advanced or unresectable sarcoma, the mPFS was 6 months (95%CI: 5-12 months), and the mOS was 16 months (95%CI: 10-28 months). The ORR was 10.8% (4/37), and the DCR was 18.9% (7/37). Subgroup analysis showed no significant differences in mPFS (p=0.11) and mOS (p=0.88) between patients with PD-L1 negative/positive expression. There were also no significant differences in mPFS (p=0.13) or mOS (p=0.72) between PD-1 inhibitor monotherapy and combination therapy. Additionally, there were no significant differences in mPFS (p=0.52) or mOS (p=0.49) between osteogenic sarcoma and soft tissue sarcoma. Furthermore, the results showed no significant differences in mPFS (p=0.66) or mOS (p=0.96) between PD-1 inhibitors combined with targeted therapy and PD-1 inhibitors combined with AI chemotherapy. Among the 6 patients receiving adjuvant therapy after surgery, the mPFS was 15 months (95%CI: 6-NA months), and the mOS was not reached. In terms of safety, most adverse events were mild (grade 1-2) and manageable. The most severe grade 4 adverse events were bone marrow suppression, which occurred in 4 patients but resolved after treatment. There was also one case of a grade 4 adverse event related to hypertension.ConclusionImmunotherapy is an effective treatment modality for sarcoma with manageable safety. Further inclusion of more patients or prospective clinical trials is needed to validate these findings.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1292325/fullsarcomaimmunotherapyefficacyadverse eventtwo-center |
| spellingShingle | Zhichao Liao Zhichao Liao Jianjin Teng Tao Li Haotian Liu Haotian Liu Ting Li Ting Li Chao Zhang Chao Zhang Ruwei Xing Ruwei Xing Sheng Teng Sheng Teng Yun Yang Yun Yang Jun Zhao Jun Zhao Wanyi Xiao Wanyi Xiao Gengpu Zhang Gengpu Zhang Mulin Jun Li Weitao Yao Jilong Yang Jilong Yang Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study Frontiers in Immunology sarcoma immunotherapy efficacy adverse event two-center |
| title | Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study |
| title_full | Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study |
| title_fullStr | Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study |
| title_full_unstemmed | Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study |
| title_short | Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study |
| title_sort | evaluation of the efficacy and safety of immunotherapy in sarcoma a two center study |
| topic | sarcoma immunotherapy efficacy adverse event two-center |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1292325/full |
| work_keys_str_mv | AT zhichaoliao evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT zhichaoliao evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT jianjinteng evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT taoli evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT haotianliu evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT haotianliu evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT tingli evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT tingli evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT chaozhang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT chaozhang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT ruweixing evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT ruweixing evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT shengteng evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT shengteng evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT yunyang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT yunyang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT junzhao evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT junzhao evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT wanyixiao evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT wanyixiao evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT gengpuzhang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT gengpuzhang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT mulinjunli evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT weitaoyao evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT jilongyang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy AT jilongyang evaluationoftheefficacyandsafetyofimmunotherapyinsarcomaatwocenterstudy |